Back to top

Analyst Blog

Takeda Pharmaceutical Company Limited (TKPYY) recently announced that it has mutually terminated its worldwide agreement with Amylin Pharmaceuticals, Inc., a wholly-owned subsidiary of Bristol-Myers Squibb (BMY). 

Takeda and Amylin had signed an agreement in October 2009 for the co-development and commercialization of obesity compounds. However, back in 2011, both companies decided to discontinue the development of obesity candidate, pramlintide/metreleptin. At that time, pramlintide/metreleptin had been in a phase II program.
On a financial basis, the termination of the partnership will not affect Takeda’s business in fiscal 2012. Takeda said that it will continue to focus on obesity as well other core therapeutic areas. Obesity is an attractive market that could be worth many billions of dollars. Moreover, obesity is linked to increased health risk of several medical conditions. Recently approved obesity treatments include Vivus Pharma’s (VVUS - Analyst Report) Qnexa and Arena Pharma’s (ARNA - Snapshot Report) Belviq.
Meanwhile, we currently have a Neutral recommendation on Bristol-Myers, which carries a Zacks #3 Rank (Hold) in the short run. The company is going through a challenging phase given the genericization of blockbuster blood-thinner Plavix. Bristol-Myers is looking to combat the generic threat through partnering deals and acquisitions. Towards fulfilling this objective and bolstering its position in the lucrative diabetes market, Bristol-Myers acquired Amylin in August 2012. 
We note that the Amylin acquisition is the second major deal for Bristol-Myers this year. In February 2012, Bristol-Myers had purchased Inhibitex, Inc., for $2.5 billion targeting the lucrative hepatitis C virus (HCV) market. 
Pharma stocks that currently look attractive include companies like Novo-Nordisk (NVO - Analyst Report) and Allergan Inc. (AGN - Analyst Report). Both companies carry a Zacks #2 Rank (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
PANTRY INC PTRY 21.02 +2.09%
INTEL CORP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%